Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome (IBS)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In the investigators study, the investigators will focus on the screening of the related proteins and miRNA to IBS in order to reveal the possible clues or molecular mechanism for this disorder.
| Condition |
|---|
|
Irritable Bowel Syndrome Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Colonic Diseases Colonic Diseases, Functional |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Screening and Identification of Abnormal Expression Proteins and miRNA From Colonic Mucosa of Patients With Irritable Bowel Syndrome. |
The investigators enrolled IBS-D and IBS-C patients on the Rome III criteria and healthy volunteers as normal control group. Biopsies were taken from the cecum and sigmoid colon under direct vision. Five pieces were taken separately at each site. Four pieces were processed by cold saline water and frozen in liquid nitrogen immediately while the other one was fixed in formalin and then embedded in paraffin three days later.
| Estimated Enrollment: | 180 |
| Study Start Date: | January 2006 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
For the proteomic procedures, Our study groups extracted proteins from the cecum and sigmoid colon samples and ran on the two-dimensional gel electrophoresis (2-DE). The proteins on 2-DE were visualized by the silver stain, and then gel maps were scanned and analyzed with the Image Master 2D Elite. The obvious abnormal protein spots were identified by the mass spectrometry. Western blot 、 immunohistochemistry 、 mRNA and miRNA were also performed for further verification of the proteins.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
IBS patients (IBS-D and IBS-C)and healthy control
Inclusion Criteria:
- Patients with symptoms meeting Rome III criteria for diagnosis of IBS-C and IBS-D
Exclusion Criteria:
- Patients with organic illnesses or a history of major abdominal surgery
- Major psychotic episode, mental retardation or dementia
- Pregnant women and lactational women
- Postinfectious IBS, PI-IBS
Contacts and Locations| Study Chair: | YANG Yun-sheng, MD | Chinese PLA General Hospital |
| Principal Investigator: | ZHANG Chun-yan, doctor | Chinese PLA General Hospital |
| Principal Investigator: | WANG Weifeng, doctor | Chinese PLA General Hospital |
| Principal Investigator: | YAO XIN, DOCTOR | Chinese PLA General Hospital |
| Principal Investigator: | PENG LIHUA, DOCTOR | Chinese PLA General Hospital |
| Principal Investigator: | YU YUANZI, DOCTOR | Chinese PLA General Hospital |
More Information
No publications provided
| Responsible Party: | YANG Yun-sheng, ChinaPLAGH |
| ClinicalTrials.gov Identifier: | NCT01028898 History of Changes |
| Other Study ID Numbers: | IBS and metabolism |
| Study First Received: | December 8, 2009 |
| Last Updated: | February 10, 2011 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Chinese PLA General Hospital:
|
IBS proteomics fluorescent quantitation polymerase chain reaction Western blot |
immunohistochemistry staining (IHC) ATP content micRNA |
Additional relevant MeSH terms:
|
Colonic Diseases Colonic Diseases, Functional Digestive System Diseases |
Gastrointestinal Diseases Intestinal Diseases Irritable Bowel Syndrome |
ClinicalTrials.gov processed this record on May 19, 2013